26 completed, 5 terminated, 4 withdrawn, 3 unknown. 11 Phase 3, 6 Phase 2, 4 Phase 4, 2 Not applicable, 1 Phase 1.
Follow Von Willebrand Disease: new trials by email Literature Review of Von Willebrand Disease trials Research Report on Von Willebrand Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age Wilate - Von Willebrand Disease | Phase 3 | Completed | Octapharma | 12 | 2021-09-22 | 2026-02-20 |
| Latin-American Von Willebrand Disease Registry Observation - Von Willebrand Disease | Unknown | Academia Nacional de Medicina | 500 | 2020-02-01 | 2020-02-21 | |
| Von Willebrand Disease in the Netherlands Von Willebrand Disease | Unknown | Erasmus Medical Center | 1100 | 2019-07-28 | 2020-08-17 | |
| rVWF IN PROPHYLAXIS von Willebrand factor (Recombinant), Antihemophilic Factor (Recombinant) - Von Willebrand Disease | Phase 3 | Completed | Takeda | 29 | 2017-11-16 | 2021-08-06 |
| A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) Vonicog alfa, Antihemophilic Factor (Recombinant) - Von Willebrand Disease | Phase 3 | Completed | Baxalta now part of Shire | 47 | 2017-11-06 | 2026-05-15 |
| Molecular and Clinical Profile of Von Willebrand Disease in Spain VWF gene analysis - Von Willebrand Disease | Completed | Spanish Society of Thrombosis and Haemostasis | 790 | 2017-10-03 | 2025-03-12 | |
| Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding Non interventional study - Von Willebrand Disease | Completed | Nantes University Hospital | 70 | 2017-02-22 | 2022-06-10 | |
| The Effect of the Nutraceutical "Hemofix" on the Coagulation System HEMOFIX - Von Willebrand Disease, Menorrhagia | Not applicable | Withdrawn | Hadassah Medical Organization | 2016-09-01 | 2017-11-28 | |
| Registry of Patients With Von WilLEbrand Disease Treated With Voncento® Voncento® - Von Willebrand Disease | Completed | CSL Behring | 135 | 2015-11-23 | 2024-04-19 | |
| Study of Voncento® in Subjects With Von Willebrand Disease Voncento - Von Willebrand Disease | Phase 4 | Completed | CSL Behring | 26 | 2015-10-05 | 2018-05-16 |
| Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery Recombinant von Willebrand Factor (rVWF) - Von Willebrand Disease | Phase 3 | Completed | Baxalta now part of Shire | 24 | 2015-04-01 | 2021-05-19 |
| Willebrand International Non-interventional Global Surveillance Von Willebrand Disease | Completed | Laboratoire français de Fractionnement et de Biotechnologies | 80 | 2014-03-01 | 2018-08-08 | |
| Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease plasma-derived FVIII/VWF concentrate - Von Willebrand Disease | Phase 4 | Withdrawn | Grifols Therapeutics LLC | 2013-12-01 | 2026-05-22 | |
| Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador Von Willebrand Disease, Hemophilia A | Completed | Universidad del Azuay | 81 | 2013-03-01 | 2013-07-03 | |
| Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease Patients using Wilate as standard of care - Von Willebrand Disease | Completed | Octapharma | 120 | 2012-10-01 | 2021-01-19 | |
| Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD) Recombinant von Willebrand factor (rVWF), Placebo, Recombinant factor VIIII (rFVIII) - Von Willebrand Disease | Phase 3 | Completed | Baxalta now part of Shire | 49 | 2011-11-01 | 2021-05-19 |
| Extension Study of Biostate in Subjects With Von Willebrand Disease Biostate - Von Willebrand Disease | Phase 3 | Completed | CSL Behring | 20 | 2010-10-01 | 2017-10-03 |
| Study of Biostate® in Children With Von Willebrand Disease Biostate - Von Willebrand Disease | Phase 3 | Completed | CSL Behring | 17 | 2010-08-01 | 2017-10-03 |
| Evaluation of Menses in Congenital Bleeding Disorders Von Willebrand Disease, Congenital Coagulation Factors Deficiency | Unknown | University of L'Aquila | 30 | 2010-02-01 | 2010-12-17 | |
| Efficacy and Safety of IL-11 in DDAVP Unresponsive Neumega (Oprelvekin, Interleukin 11, IL-11) - Hemophilia A, Von Willebrand Disease | Phase 2 | Completed | University of Pittsburgh | 9 | 2010-01-01 | 2016-03-02 |
Showing 20 of 38. Sign in to see all of them.
von Willebrand Diseases (38) · Hemophilia A (5) · Menorrhagia (4) · Hematologic Diseases (3) · Blood Coagulation Disorders (2) · Blood Platelet Disorders (2) · Disease (2) · Hemorrhage (2) · Hemostatic Disorders (2) · Aortic Valve Stenosis (1) · Hemophilia B (1) · Thrombosis (1)
Blood Coagulation Disorders, Inherited (38) · Coagulation Protein Disorders (38) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (38) · Genetic Diseases, Inborn (38) · Hemic and Lymphatic Diseases (38) · Hemorrhagic Disorders (38) · Blood Coagulation Disorders (36) · Blood Platelet Disorders (36) · Hematologic Diseases (35) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Cardiovascular Diseases (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4)
Factor VIII (6) · Interleukin-11 (4) · oprelvekin (4) · von Willebrand Factor (4) · optivate (3) · ARC 1779 (1) · Deamino Arginine Vasopressin (1) · F8 protein, human (1) · Observation (1) · Sodium Chloride (1) · Standard of Care (1) · Tranexamic Acid (1)
CSL Behring (7) · Baxalta now part of Shire (4) · Bio Products Laboratory (3) · Erasmus Medical Center (2) · Margaret Ragni (2) · Octapharma (2) · University of Pittsburgh (2) · Academia Nacional de Medicina (1) · Archemix Corp. (1) · Centers for Disease Control and Prevention (1) · Grifols Biologicals, LLC (1) · Grifols Therapeutics LLC (1) · Hadassah Medical Organization (1) · Laboratoire français de Fractionnement et de Biotechnologies (1) · Nantes University Hospital (1)
United States (16) · Germany (11) · United Kingdom (9) · Italy (7) · Russia (7) · Spain (7) · Netherlands (6) · Ukraine (6) · Austria (5) · Canada (5) · Czechia (5) · Poland (5) · France (4) · Belgium (3) · Bulgaria (3)
Margaret V. Ragni, MD, MPH (3) · Frank WG Leebeek, MD, PhD (2) · Karina Meijer, MD, PhD (2) · Arja de Goede-Bolder, MD (1) · Britta AP Laros-van Gorkom, MD, PhD (1) · Britta Laros-van Gorkom, MD, PhD (1) · Charles Hay, MD (1) · David G. Barnes, Dr. (1) · David Varon, Prof (1) · Deborah Brown, MD (1) · Erik Berntorp, MD, PhD (1) · Eva M de Wee, MD (1)
PMID 16247740, PMID 16359502, PMID 16634745, PMID 16634746, PMID 16889557, PMID 16985174, PMID 17059476, PMID 17488667, PMID 18315556, PMID 18344424, PMID 19277422, PMID 19566550, PMID 19786936, PMID 20801902, PMID 21199188, PMID 21251206, PMID 21833452, PMID 22102193, PMID 22197721, PMID 22507569, PMID 22823000, PMID 23238591, PMID 23349392, PMID 23633542, PMID 23777763, PMID 25077350, PMID 25381842, PMID 25688461, PMID 2584182, PMID 26239086, PMID 26245874, PMID 28971901, PMID 29924855, PMID 30361419, PMID 31041796, PMID 32135566, PMID 35439298, PMID 36861346
2009 (2), 2016 (2), 2008 (1), 2014 (1), 2023 (1)